Q-omics provides the consensus-scored SPRR2D profile across patient tissues and cancer cell-line models. SPRR2D expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPRR2D is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, SPRR2D RNA expression shows 10,820 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, COAD, and ESCA as cancer lineages where SPRR2D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPRR2D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPRR2D survival associations across molecular data types. SPRR2D RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPRR2D RNA expression–survival associations across cancer types. High SPRR2D expression shows unfavorable associations in KIRC, LIHC, BLCA, ACC, COAD and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPRR2D RNA expression.
This table summarizes SPRR2D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SPRR2D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPRR2D shows lower tumor expression in KIRC and KICH and higher tumor expression in COAD, LUSC, LUAD and PAAD. The COAD box plot shows higher SPRR2D RNA expression in tumor versus normal tissue (log2 FC = +0.771, t-test p < 0.001).
This table shows molecular features associated with SPRR2D in patient tissues and cancer cell lines. In patient samples, SPRR2D shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SPRR2D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
